68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
Study Details
Study Description
Brief Summary
To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs; e.g., FAPI-04 and FAPI-46), which have shown promising results in the diagnosis of cancer and various other diseases in recent years, have become the focus of much productive research. Despite this, one major issue is that these FAPI molecules have a relatively short tumor retention time, which may limit their use in targeted radionuclide therapy applications. As a result, 68Ga-DOTA-F2, a novel dimeric FAPI molecule, was developed to increase tracer uptake and retention in tumors for potential therapeutic or theranostic applications. In preclinical study, 68Ga-DOTA-F2 has shown better tumor uptake and longer tumor retention time than 68Ga-FAPI in mouse tumor models. Our study will assess image quality and evaluate the diagnostic performance of 68Ga-DOTA-F2. Patients with histologically confirmed malignant tumors will be prospectively recruited in this study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 68Ga-DOTA-F2 PET/CT and 18F-FDG Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time. |
Diagnostic Test: 68Ga-DOTA-F2 PET/CT and 18F-FDG
Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.
|
Outcome Measures
Primary Outcome Measures
- Standardized uptake value (SUV) [through study completion, an average of 1 year]
Standardized uptake value (SUV) of 68Ga-DOTA-F2 and 18F-FDG for each primary tumor of subject or suspected lymph metastasis
- Lession detection ability [through study completion, an average of 1 year]
Lession number detected by 68Ga-DOTA-F2 and 18F-FDG PET/CT
Secondary Outcome Measures
- Sensitivity [through study completion, an average of 1 year]
The sensitivity of 68Ga-DOTA-F2 PET/CT and 18F-FDG PET/CT
- Specificity [through study completion, an average of 1 year]
The specificity of 68Ga-DOTA-F2 PET/CT and 18F-FDG PET/CT
- Radiation Dosimetry [30 days]
Mean absorbed radiation doses were estimated using the source and target organ framework. Five patients with different cancers underwent serial 68Ga-DOTA-F2 PET/CT scans at five-time points following radiotracer injection: 5 minutes, 15 minutes, 30 minutes, 1 hour, and 3 hours. The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and body remainder. OLINDA/EXM software was used to fit and integrate the kinetic organ activity data to yield total body and organ time-integrated activity coefficients/residence times and finally organ absorbed doses.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is aged 18 years or older
-
Signed Informed Consent
-
Subject is pathologically confirmed with a malignant tumor
-
Subject is judged to be in good general condition by the investigator based on medical history, physical examination including vital signs and clinical laboratory tests, besides the diagnosis of malignant tumor
-
Female subjects should be post-menopausal or surgically sterile or using effective contraceptive with the negative pregnancy test
Exclusion Criteria:
-
Subject has a previous or ongoing recurrent or chronic disease, other than malignant tumor, at high risk to interfere with the evaluation of the trial according to the judgment of the investigator
-
Subject with non-malignant lesions;
-
Subject with the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
-
Subject is potentially pregnant (serum and urinary hCG test will be performed in women where pregnancy is not excluded) or is breast-feeding
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Peking union medical college hospital | Beijing | Beijing | China | 10010 |
Sponsors and Collaborators
- Peking Union Medical College Hospital
Investigators
- Principal Investigator: Fang Li, MD, Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- I-22PJ292